Verastem Oncology to End RAMP 203 Trial of Lung Cancer Treatment

Dow Jones2025-12-30

By Katherine Hamilton

Verastem Oncology said it will discontinue its RAMP 203 trial of a lung cancer treatment.

The Boston biopharmaceutical company said Monday it plans to focus resources instead on clinical development of VS-7375 to treat non-small cell lung cancer.

There will be no further enrollment in the RAMP 203 trial and patients currently enrolled will have the option to continue treatment per investigator discretion.

The decision reflects the evolving treatment landscape and the strategic prioritization of programs with the greatest potential impact for patients, Verastem said.

While avutometinib and defactinib combined well with a G12C inhibitor in the RAMP trial, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Chief Medical Officer John Hayslip said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 29, 2025 16:17 ET (21:17 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595375873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595375873","market":"hk","top_or_hot":-1,"title":"Verastem Oncology to End RAMP 203 Trial of Lung Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology said it will discontinue its RAMP 203 trial of a lung cancer treatment. \n</p>\n<p>\n  The Boston biopharmaceutical company said Monday it plans to focus resources instead on clinical development of VS-7375 to treat non-small cell lung cancer. \n</p>\n<p>\n  There will be no further enrollment in the RAMP 203 trial and patients currently enrolled will have the option to continue treatment per investigator discretion. \n</p>\n<p>\n  The decision reflects the evolving treatment landscape and the strategic prioritization of programs with the greatest potential impact for patients, Verastem said. \n</p>\n<p>\n  While avutometinib and defactinib combined well with a G12C inhibitor in the RAMP trial, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Chief Medical Officer John Hayslip said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2025 16:17 ET (21:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Oncology to End RAMP 203 Trial of Lung Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Oncology to End RAMP 203 Trial of Lung Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-30 05:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology said it will discontinue its RAMP 203 trial of a lung cancer treatment. \n</p>\n<p>\n  The Boston biopharmaceutical company said Monday it plans to focus resources instead on clinical development of VS-7375 to treat non-small cell lung cancer. \n</p>\n<p>\n  There will be no further enrollment in the RAMP 203 trial and patients currently enrolled will have the option to continue treatment per investigator discretion. \n</p>\n<p>\n  The decision reflects the evolving treatment landscape and the strategic prioritization of programs with the greatest potential impact for patients, Verastem said. \n</p>\n<p>\n  While avutometinib and defactinib combined well with a G12C inhibitor in the RAMP trial, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Chief Medical Officer John Hayslip said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 29, 2025 16:17 ET (21:17 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2595375873","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595375873","pubTimestamp":1767043020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology said it will discontinue its RAMP 203 trial of a lung cancer treatment.The Boston biopharmaceutical company said Monday it plans to focus resources instead on clinical development of VS-7375 to treat non-small cell lung cancer.There will be no further enrollment in the RAMP 203 trial and patients currently enrolled will have the option to continue treatment per investigator discretion.The decision reflects the evolving treatment landscape and the strategic prioritization of programs with the greatest potential impact for patients, Verastem said.While avutometinib and defactinib combined well with a G12C inhibitor in the RAMP trial, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Chief Medical Officer John Hayslip said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","RAMP":"LiveRamp Holdings, Inc.","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","BK4139":"生物科技","LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4134":"信息科技咨询与其它服务","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","VSTM":"Verastem"},"translate_title":"Verastem Oncology将结束RAMP 203肺癌治疗试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5,"RAMP":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\nVerastem Oncology said it will discontinue its RAMP 203 trial of a lung cancer treatment. \n\n\n  The Boston biopharmaceutical company said Monday it plans to focus resources instead on clinical development of VS-7375 to treat non-small cell lung cancer. \n\n\n  There will be no further enrollment in the RAMP 203 trial and patients currently enrolled will have the option to continue treatment per investigator discretion. \n\n\n  The decision reflects the evolving treatment landscape and the strategic prioritization of programs with the greatest potential impact for patients, Verastem said. \n\n\n  While avutometinib and defactinib combined well with a G12C inhibitor in the RAMP trial, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Chief Medical Officer John Hayslip said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2025 16:17 ET (21:17 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595375873","isCrawlerRequest":true}